Why more needs to be known about RBE effects in modern radiotherapy

Applied Radiation and Isotopes

Volumn 67, Issue 3, 2009, Pages 387-392

  Dale, R G ^a   Jones, B ^b   Carabe Fernandez A ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Carbon ions; Contact radiotherapy; Linear quadratic model; Particle beam therapy; Permanent implant brachytherapy; Protons; Targeted radiotherapy

Indexed keywords

ATOMS; BIOACCUMULATION; IONS; PARTICLE BEAM DYNAMICS; PARTICLE BEAMS; PROTONS; TUMORS;

CARBON IONS; CONTACT RADIOTHERAPY; LINEAR-QUADRATIC MODEL; PARTICLE BEAM THERAPY; PERMANENT IMPLANT BRACHYTHERAPY; TARGETED RADIOTHERAPY;

RADIOTHERAPY;

ARTICLE; CANCER THERAPY; MATHEMATICAL COMPUTING; MICRODOSIMETRY; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RELATIVE BIOLOGIC EFFECTIVENESS; TREATMENT PLANNING;

HUMANS; IONS; NEOPLASMS; PROTONS; RADIOTHERAPY; RELATIVE BIOLOGICAL EFFECTIVENESS;

EID: 58549086325     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2008.06.013     Document Type: Article

References (50)

1. 103Pd. Phys. Med. Biol. 46 (2001) 2557-2569
2. Armpilia C.I., Dale R.G., Coles I.P., Jones B., and Antipas V. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int. J. Radiat. Oncol. Biol. Phys. 55 (2003) 378-385
3. Barendsen G.W. Dose fractionation, dose-rate and iso-effect relationships for normal tissues. Int. J. Radiat. Oncol. Biol. Phys. 8 (2002) 1981-1997
4. Bentzen S.M. Dose response relationships in radiotherapy. In: Steel G.G. (Ed). Basic Clinical Radiobiology. third ed. (2002), Arnold, London 94-104
5. Bentzen S.M., Dorr W., Anscher M.S., Denham J.W., Hauer-Jensen M., Marks L.B., and Williams J. Normal tissue effects: reporting and analysis. Semin. Radiat. Oncol. 13 (2003) 189-202
6. Bodey R.K., Evans P.M., and Flux G.D. Application of the linear-quadratic model to combined modality radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 59 (2004) 228-241
7. Brahme A. Recent advances in light ion radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 603-616
8. Brenner D.J., Leu C.S., Beatty J.F., and Shefer R.E. Clinical relative biological effectiveness of low energy X-rays emitted by miniature X-ray devices. Phys. Med. Biol. 44 (1999) 323-333
9. Broerse J.J., and Barendsen G.W. Relative biological effectiveness of fast neutrons for effects on normal tissues. Curr. Top. Radiat. Res. Q. 8 (1973) 305-350
10. min) into the linear-quadratic model and the potential for improved radiobiological analysis of high-LET treatments. Int. J. Radiat. Biol. 83 1 (2007) 27-39
11. Chadwick K.H., and Leenhouts H.P. A molecular theory of cell survival. Phys. Med. Biol. 18 (1973) 78-87
12. Dale R.G. Time-dependent tumour repopulation factors in linear-quadratic equations-implications for treatment strategies. Radiother. Oncol. 15 (1989) 371-381
13. Dale R.G. The radiobiology of Papillon-type treatments. Clin. Oncol. 19 (2007) 649-654
14. Dale R.G., and Jones B. The clinical radiobiology of brachytherapy. Br. J. Radiol. 71 (1998) 465-483
15. Dale R.G., and Jones B. The assessment of RBE effects using the concept of biologically effective dose. Int. J. Radiat. Oncol. Biol. Phys. 43 (1999) 639-645
16. Dale R.G., Jones B., and Sinclair J.A. Dose equivalents of tumour repopulation during radiotherapy: the potential for confusion. Br. J. Radiol. 73 (2000) 892-894
17. Fowler J.F. Is there an optimum overall time for head and neck radiotherapy? A review, with new modelling. Clin. Oncol. 19 (2007) 8-22
18. Goodhead D.T. Inactivation and mutation of cultured mammalian cells by aluminium characteristic ultrasoft X-rays: III. Implications of the theory of dual radiation action. Int. J. Radiat. Biol. 32 1 (1977) 43-70
19. Hall E.J. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int. J. Radiat., Oncol. Biol. Phys. 65 1 (2006) 1-7
20. Hawkins R.B. A microdosimetric-kinetic model for the effect of non-Poisson distributions of lethal lesions on the variation of RBE with LET. Radiat. Res. 160 (2003) 61-69
21. Herskind C., Steil V., Kraus-Tiefenbacher U., and Wenz F. Radiobiological aspects of intraoperative radiotherapy (IORT) with isotropic low-energy X-rays for early breast cancer. Radiat. Res. 163 (2005) 208-215
22. Hoshi M., Antoku S., Nakamura N., Russel W.J., Miller R.C., Sawada S., Mizuno M., and Nishio S. Soft X-ray dosimetry and RBE for survival of Chinese hamster V79 cells. Int. J. Radiat. Biol. 54 (1988) 577-591
23. Jones B. The case for particle therapy. Br. J. Radiol. 79 (2006) 24-31
24. Jones B., and Dale R.G. Radiobiological modelling and clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 48 (2000) 259-265
25. Jones B., and Dale R.G. Further radiobiologic modelling of palliative radiotherapy: use of virtual trials. Int. J. Radiat. Oncol. Biol. Phys. 69 (2007) 221-229
26. Jones B., Tan L.T., and Dale R.G. Derivation of the optimum dose per fraction from the linear-quadratic model. Br. J. Radiol. 68 (1995) 894-902
27. Jones B., Dale R.G., Deehan C., Hopkins K.I., and Morgan D.A. The role of biologically effective dose (BED) in clinical oncology. Clin. Oncol. 13 (2001) 71-81
28. Jones B., Cárabe-Fernández A., and Dale R.G. Calculation of high-LET radiotherapy dose required for compensation of overall treatment time extensions. Br. J. Radiol. 79 (2006) 254-257
29. Jurcic J.G. Antibody therapy for residual disease in acute myelogenous leukaemia. Crit. Rev. Oncol. Hematol. 38 (2001) 37-45
30. Kalogianni E., Flux G.D., and Malroda A. The use of BED and EUD concepts in heterogeneous radioactivity distributions on a multicellular scale for targeted radionuclide therapy. Cancer Biother. Radiopharm. 22 (2007) 143-150
31. Kellerer A.M., and Rossi H.H. The theory of dual radiation action. Curr. Top. Radiat. Res. Q. 8 (1972) 85-158
32. Kramer M., and Scholz M. Rapid calculation of biological effects in ion radiotherapy. Phys. Med. Biol. 51 (2006) 1959-1970
33. Krengli M., and Orecchia R. Medical aspects of the National Centre for Oncological Hadrontherapy (CNAO-Centro Nazionale Adronterapia Oncologica) in Italy. Radiother. Oncol. 73 Suppl. 2 (2004) S21-S23
34. Ling C.C., Li W.X., and Anderson L.L. The relative biological effectiveness of I-125 and Pd-103. Int. J. Radiat. Oncol. Biol. Phys. 32 (1995) 373-378
35. Lodge M., Pijls-Johannesma M., Stirk L., Munro A.J., De Russcher D., and Jeffersonn T. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother. Oncol. 83 (2007) 110-122
36. McDevitt M.R., Barendswaard E., Ma D., Lai L., Curcio M.J., Sgouros G., Ballangrud A.M., Yang W.H., Finn R.D., Pellegrini V., Geerlings Jr. M.W., Lee M., Brechbiel M.W., Bander N.H., Cordon-Cardo C., and Scheinberg D.A. An alpha-particle emitting antibody ([Bi-213]J59) for radioimmunotherapy of prostate cancer. Cancer Res. 60 (2000) 6095-6100
37. Mulford D.A., Scheinberg D.A., and Jurcic J.G. The promise of targeted α-particle therapy. J. Nucl. Med. 46 Suppl. 1 (2005) 199S-204S
38. Paganetti H. Significance and implementation of RBE variations in proton beam therapy. Technol. Cancer Res. Treat. 2 (2003) 413-426
39. RCR, 2003. Equipment, workload and staffing in radiotherapy in the UK 1997-2002. Royal College of Radiologists, BFC(03)3.
40. Roberts S.A., and Hendry J.H. Time factors in larynx tumour radiotherapy: lag times and inter-tumour heterogeneity in clinical datasets from four centres. Int. J. Radiat. Oncol. Biol. Phys. 45 (1999) 1247-1257
41. Scalliet P., and Wambersie A. Which RBE for iodine 125 in clinical applications?. Radiother. Oncol. 9 (1987) 221-230
42. Sgouros G., Ballangrud A.M., Jurcic J.G., McDevitt M.R., Humm J.L., Erdi Y.E., Mehta B.M., Finn R.D., Lawson S.M., and Scheinberg D.A. Pharmacokinetics and dosimetry of an alpha-particle emitter labelled antibody: Bi-213-HuM195 (anti-CD33) in patients with leukaemia. J. Nucl. Med. 40 (1999) 1935-1946
43. 60Co gamma-rays, 55 kVp X-rays, 250 kVp X-rays and 11 MeV electrons at low doses. Int. J. Radiat. Biol. 61 (1992) 345-353
44. Wambersie A. RBE, reference RBE and clinical RBE: applications of these concepts in hadron therapy. Strahlenther. Onkol. 175 Suppl. 2 (1999) 39-43
45. Weyrather, W.K., 2004. Medical applications of ion beams. In: The Euroschool Lectures on Physics with Exotic Beams, vol. 1. Springer, Berlin/Heidelberg, pp. 469-490.
46. Weyrather W.K., and Debus J. Particle beams for cancer therapy. Clin. Oncol. 15 (2003) S23-S28
47. Weyrather W.K., and Kraft G. RBE of carbon ions: experimental data and the strategy of RBE calculation for treatment planning. Radiother. Oncol. 73 Suppl. 2 (2004) S161-S169
48. Withers H.R., Thames H.D., and Peters L.J. Biological bases for high RBE values for late effects of neutron irradiation. Int. J. Radiat. Oncol. Biol. Phys. 8 (1982) 2071-2076
49. 103Pd brachytherapy sources using the concept of proximity function. Med. Phys. 25 (1998) 2186-2189
50. Zalutsky M.R., and Pozzi O.R. Radioimmunotherapy with alpha-particle emitting radionuclides. Q. J. Nucl. Med. Mol. Imaging 48 (2004) 289-296